Dystrophin immunity in Duchenne's muscular dystrophy.
Level II
Where this comes from
- Record sourced from PubMed, PMID 20925545.
- Also identified by DOI 10.1056/NEJMoa1000228 and PMC identifier 3014106.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report on delivery of a functional dystrophin transgene to skeletal muscle in six patients with Duchenne's muscular dystrophy. Dystrophin-specific T cells were detected after treatment, providing evidence of transgene expression even when the functional protein was not visualized in skeletal muscle. Circulating dystrophin-specific T cells were unexpectedly detected in two patients before vector treatment. Revertant dystrophin fibers, which expressed functional, truncated dystrophin from the deleted endogenous gene after spontaneous in-frame splicing, contained epitopes targeted by the autoreactive T cells. The potential for T-cell immunity to self and nonself dystrophin epitopes should be considered in designing and monitoring experimental therapies for this disease. (Funded by the Muscular Dystrophy Association and others; ClinicalTrials.gov number, NCT00428935.).
Medical subject headings
- Autoantibodies
- Dystrophin
- Genetic Therapy
- Immunity, Cellular
- Muscular Dystrophy, Duchenne
- T-Lymphocytes